Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ElixaMD vs Unique Physique

ElixaMD
Graded #251

Higher grade

vs+2.1000000000000014
Unique Physique
Graded #290

Lower grade

The verdict

ElixaMD takes it — 63.7/100 to 61.6/100.

ElixaMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ElixaMD is a doctor-guided online weight-loss telehealth offering compounded semaglutide injections from $179 the first month, with free shipping, no membership, no contract, and no insurance required.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueUnique Physique +27
51
78
Dose & formulationUnique Physique +9
52
61
Clinical oversightElixaMD +30
92
62
Labs & monitoringElixaMD +13
63
50
FulfillmentElixaMD +29
76
47
Contract termsUnique Physique +10
45
55
ElixaMD · left barUnique Physique · right bar

The numbers

MetricElixaMDUnique Physique
WeighScore63.7/10061.6/100
GradeCC
Scorecard rank#251#290
Semaglutide$179/mo (starting dose, first-month rate, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
ElixaMD

Graded #251 · C

Strengths

  • Compounded semaglutide from $179 first month with free shipping, no membership, no contract, and no insurance required
  • Genuinely all-inclusive: 1:1 physician guidance, free dietician visits and care coaching, 24/7 support, and an all-in-one patient portal
  • Names its compounding pharmacies (RedRock Pharmacy, Beaker Pharmacy) — more transparent than most compounded sellers
  • HSA/FSA eligible; full legal suite (Terms, Privacy, Privacy Practices, Refund, Medical Consent, California Bill of Rights)

Where it loses points

  • $179 is a first-month/intro price — ongoing monthly cost is higher (tiers to ~$249-$299)
  • Compounded semaglutide is not FDA-approved (the site discloses this) — not brand Wegovy or Ozempic
  • Appears to offer compounded semaglutide only — tirzepatide is not advertised
  • Displays a generic LegitScript Certified badge but no verifiable seal/listing; state-availability list not published
Unique Physique

Graded #290 · C

Strengths

  • Legal entity disclosed (Unique Physique, LLC) with Louisiana governing law — better than opaque DTC competitors
  • Named medical director (Reena John, DO) — uncommon at this price tier
  • Brick-and-mortar clinic in Baton Rouge, LA offers an in-person option vs ship-only competitors
  • Transparent two-tier flat pricing ($195/mo and $325/mo) — no dose-escalation surprises
  • Brand-name routing option ($25/mo) sends an Rx to your own pharmacy for Wegovy/Zepbound/Ozempic/Mounjaro

Where it loses points

  • GLP-1 drug molecules aren't named on the pricing or service pages — you can't confirm what the $195/mo and $325/mo plans contain without calling
  • Pharmacy partner not named — can't verify licensure or 503A vs 503B status
  • No FDA compounded-medication disclaimer on any audited page
  • States served not listed — only "licensed clinicians in the patient's state"
  • Non-refundable per the Terms; medication not picked up within 60 days is discarded with no refund

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard